Klingman & Associates, LLC Gilead Sciences, Inc. Transaction History
Klingman & Associates, LLC
- $1.97 Billion
- Q3 2025
A detailed history of Klingman & Associates, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Klingman & Associates, LLC holds 2,315 shares of GILD stock, worth $287,268. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,315Holding current value
$287,268% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding GILD
# of Institutions
2,369Shares Held
1.01BCall Options Held
8.63MPut Options Held
7.39M-
Black Rock Inc. New York, NY121MShares$15 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.8 Billion0.21% of portfolio
-
State Street Corp Boston, MA59.1MShares$7.33 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA45.2MShares$5.61 Billion0.72% of portfolio
-
Dodge & Cox San Francisco, CA30.1MShares$3.74 Billion1.93% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $156B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...